By inhibiting the ligand–receptor interaction of PD-1/PD-L1, it is possible to prevent the activation of the PD-1/PD-L1 signaling pathway, reversing T cell fatigue and preventing immunological responses in the tumor microenvironment (Figure 6) [120]. The gene discussed is CD274; the disease is neoplasm.